Resistance to androgen-pathway drugs in prostate cancer

Comment

Emmanuel S Antonarakis et al. N Engl J Med. 2014.

. 2014 Dec 4;371(23):2234.

doi: 10.1056/NEJMc1412594.

No abstract available

Comment on

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.
Resistance to androgen-pathway drugs in prostate cancer.
Şendur MA, Akıncı MB, Yalçın B. Şendur MA, et al. N Engl J Med. 2014 Dec 4;371(23):2233. doi: 10.1056/NEJMc1412594. N Engl J Med. 2014. PMID: 25470701 No abstract available.
Resistance to androgen-pathway drugs in prostate cancer.
Ozaki Y, Miura Y, Takano T. Ozaki Y, et al. N Engl J Med. 2014 Dec 4;371(23):2233-4. doi: 10.1056/NEJMc1412594. N Engl J Med. 2014. PMID: 25470702 No abstract available.
Resistance to androgen-pathway drugs in prostate cancer.
Steinestel J, Schrader AJ, Luedeke M. Steinestel J, et al. N Engl J Med. 2014 Dec 4;371(23):2234. doi: 10.1056/NEJMc1412594. N Engl J Med. 2014. PMID: 25470703 No abstract available.